RNA vaccines: A transformational advance

Brian D Brown; Anthony S Fauci; Yasmine Belkaid; Miriam Merad

doi:10.1016/j.immuni.2023.11.009

RNA vaccines: A transformational advance

Immunity. 2023 Dec 12;56(12):2665-2669. doi: 10.1016/j.immuni.2023.11.009.

Authors

Brian D Brown¹, Anthony S Fauci², Yasmine Belkaid³, Miriam Merad⁴

Affiliations

¹ Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: brian.brown@mssm.edu.
² Georgetown University, School of Medicine and McCourt School of Public Policy, Washington, DC, USA. Electronic address: asfauci@outlook.com.
³ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: ybelkaid@niaid.nih.gov.
⁴ Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: miriam.merad@mssm.edu.

PMID: 38091944
DOI: 10.1016/j.immuni.2023.11.009

Abstract

Vaccines have stemmed many infectious diseases, but when SARS-CoV-2 emerged, traditional vaccine development would not have been fast enough. This year's Nobel Prize in Physiology or Medicine recognizes work that enabled the rapid development of mRNA vaccines, which halted the COVID-19 pandemic. The feat was a product of basic biological insights coupled with technological innovations, which have transformed vaccine design.

MeSH terms

COVID-19 Vaccines / genetics
COVID-19* / prevention & control
Humans
Pandemics / prevention & control
Vaccines* / genetics
mRNA Vaccines

Substances

mRNA Vaccines
COVID-19 Vaccines
Vaccines